Codexis, Inc. (0I0X.L)
USD 5.58
(-2.26%)
USD 5.58
(-2.26%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 57.33 Million USD | -48.47% |
| 2022 | 100.55 Million USD | 21.82% |
| 2021 | 82.54 Million USD | 49.23% |
| 2020 | 55.31 Million USD | 4.71% |
| 2019 | 52.82 Million USD | 10.11% |
| 2018 | 47.97 Million USD | 34.39% |
| 2017 | 35.69 Million USD | -8.67% |
| 2016 | 39.08 Million USD | 10.98% |
| 2015 | 35.21 Million USD | 37.67% |
| 2014 | 25.58 Million USD | 47.29% |
| 2013 | 17.36 Million USD | -69.87% |
| 2012 | 57.65 Million USD | -29.77% |
| 2011 | 82.08 Million USD | 3.74% |
| 2010 | 79.12 Million USD | 19.47% |
| 2009 | 66.23 Million USD | 77.61% |
| 2008 | 37.29 Million USD | 119.17% |
| 2007 | 17.01 Million USD | 64.85% |
| 2006 | 10.32 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 3.27 Million USD | -70.11% |
| 2024 Q3 | 8.51 Million USD | 159.79% |
| 2024 Q1 | 10.96 Million USD | -51.23% |
| 2023 FY | 51.81 Million USD | -48.47% |
| 2023 Q4 | 22.48 Million USD | 219.91% |
| 2023 Q2 | 18.14 Million USD | 114.45% |
| 2023 Q3 | 7.02 Million USD | -61.27% |
| 2023 Q1 | 8.46 Million USD | -61.4% |
| 2022 Q4 | 21.91 Million USD | -11.2% |
| 2022 Q3 | 24.68 Million USD | -9.04% |
| 2022 Q1 | 26.81 Million USD | 51.56% |
| 2022 Q2 | 27.13 Million USD | 1.18% |
| 2022 FY | 100.55 Million USD | 21.82% |
| 2021 Q3 | 29.9 Million USD | 41.48% |
| 2021 Q1 | 13.81 Million USD | -8.96% |
| 2021 Q4 | 17.69 Million USD | -40.82% |
| 2021 FY | 82.54 Million USD | 49.23% |
| 2021 Q2 | 21.13 Million USD | 53.0% |
| 2020 Q4 | 15.17 Million USD | 2.92% |
| 2020 FY | 55.31 Million USD | 4.71% |
| 2020 Q2 | 13.26 Million USD | 9.39% |
| 2020 Q1 | 12.12 Million USD | -20.46% |
| 2020 Q3 | 14.74 Million USD | 11.12% |
| 2019 Q2 | 9.54 Million USD | -14.7% |
| 2019 Q3 | 16.83 Million USD | 76.38% |
| 2019 FY | 52.82 Million USD | 10.11% |
| 2019 Q1 | 11.19 Million USD | -18.16% |
| 2019 Q4 | 15.24 Million USD | -9.45% |
| 2018 Q1 | 10.21 Million USD | -43.75% |
| 2018 Q4 | 13.67 Million USD | 3.95% |
| 2018 FY | 47.97 Million USD | 34.39% |
| 2018 Q3 | 13.15 Million USD | 20.39% |
| 2018 Q2 | 10.92 Million USD | 6.95% |
| 2017 Q1 | 4.96 Million USD | -35.32% |
| 2017 Q3 | 6 Million USD | -8.37% |
| 2017 Q2 | 6.55 Million USD | 31.96% |
| 2017 FY | 35.69 Million USD | -8.67% |
| 2017 Q4 | 18.16 Million USD | 202.31% |
| 2016 Q3 | 12.11 Million USD | -12.1% |
| 2016 FY | 39.08 Million USD | 10.98% |
| 2016 Q4 | 7.68 Million USD | -36.59% |
| 2016 Q2 | 13.78 Million USD | 150.25% |
| 2016 Q1 | 5.5 Million USD | -38.87% |
| 2015 FY | 35.21 Million USD | 37.67% |
| 2015 Q2 | 4.76 Million USD | -10.75% |
| 2015 Q1 | 5.34 Million USD | -49.81% |
| 2015 Q3 | 16.09 Million USD | 237.65% |
| 2015 Q4 | 9 Million USD | -44.04% |
| 2014 Q1 | 4.55 Million USD | -4.43% |
| 2014 Q2 | 4.44 Million USD | -2.26% |
| 2014 Q3 | 5.94 Million USD | 33.57% |
| 2014 Q4 | 10.64 Million USD | 79.19% |
| 2014 FY | 25.58 Million USD | 47.29% |
| 2013 Q1 | 5.81 Million USD | 172.67% |
| 2013 Q2 | 3.34 Million USD | -42.52% |
| 2013 Q3 | 3.44 Million USD | 3.17% |
| 2013 Q4 | 4.76 Million USD | 38.04% |
| 2013 FY | 17.36 Million USD | -69.87% |
| 2012 Q4 | 2.13 Million USD | -89.31% |
| 2012 FY | 57.65 Million USD | -29.77% |
| 2012 Q1 | 18.49 Million USD | -9.45% |
| 2012 Q3 | 19.94 Million USD | 16.77% |
| 2012 Q2 | 17.08 Million USD | -7.65% |
| 2011 Q1 | 19.38 Million USD | -10.61% |
| 2011 Q2 | 18.94 Million USD | -2.24% |
| 2011 Q3 | 23.32 Million USD | 23.09% |
| 2011 Q4 | 20.42 Million USD | -12.43% |
| 2011 FY | 82.08 Million USD | 3.74% |
| 2010 Q3 | 18.55 Million USD | 0.79% |
| 2010 Q1 | 20.48 Million USD | 5.33% |
| 2010 Q4 | 21.68 Million USD | 16.9% |
| 2010 FY | 79.12 Million USD | 19.47% |
| 2010 Q2 | 18.4 Million USD | -10.14% |
| 2009 FY | 66.23 Million USD | 77.61% |
| 2009 Q1 | 15.55 Million USD | 16.67% |
| 2009 Q4 | 19.44 Million USD | 25.91% |
| 2009 Q3 | 15.44 Million USD | -2.17% |
| 2009 Q2 | 15.78 Million USD | 1.49% |
| 2008 Q4 | 13.33 Million USD | 0.0% |
| 2008 FY | 37.29 Million USD | 119.17% |
| 2008 Q1 | 5.48 Million USD | 0.0% |
| 2007 Q1 | 3.35 Million USD | 0.0% |
| 2007 FY | 17.01 Million USD | 64.85% |
| 2006 FY | 10.32 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 135.26 Million USD | 57.615% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 76.184% |
| Viridian Therapeutics, Inc. | -1 Million USD | 5787.897% |
| Organovo Holdings, Inc. | -5.38 Million USD | 1163.908% |